Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Immune cell levels in canine gliomas could provide therapeutic targets, a study has revealed
 The findings could have implications for immotherapy-based glioma treatments in both humans and dogs.
High grade gliomas found to contain more immune cells which repress immune response. 

A new study from the NC State College of Veterinary Medicine has revealed that high-grade gliomas in dogs contain more immune cells associated with suppressing immune response than low-grade gliomas.

It is hoped that the research could have potential implications for immunotherapy-based tumour treatments in the future, for dogs and humans, as it is the most extensive exploration of immune cell infiltration so far. 

Researchers are attempting to gain a more comprehensive understanding of the interaction between glioma and the immune system in order to improve therapeutic outcomes. 

As the second most common type of tumour in dogs in the central nervous system, gliomas represent around 35 per cent of all intracranial cancers in dogs, and the shared features between canine and human gliomas make the research useful for understanding this kind of cancer in both humans and dogs. 

Examining 73 different gliomas, researchers used immunohistochemical tagging and computerised image analysis to identify the amount of each type of immune cell in each tumour. Higher numbers of regulatory T lymphocytes (Tregs) and polarised macrophages in high grade tumours over low grade tumours, but found that other types and grades of tumour showed no difference in immune cells. 

Alongside the examination of immune cell types, researchers also counted the number of macrophages in the tumours, and found that the macrophages in gliomas generally tended to be polarized towards the M2 phenotype, which are pro-inflammatory and pro-tumour. 

As reported by the NC State News Services, Gregory Krane, first author of the research, commented: “These macrophage polarization data can expand the glioma immunosuppression hypothesis by providing another mechanism by which gliomas may suppress the immune system in the dog.”

Published in July 2021 in Veterinary Pathology, the study is available to read here.

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.